Search results
Results from the WOW.Com Content Network
Meclofenoxate (INN, BAN; brand name Lucidril, also known as centrophenoxine) is a cholinergic nootropic used as a dietary supplement. [2] [3] [4] It is an ester of dimethylethanolamine (DMAE) and 4-chlorophenoxyacetic acid (pCPA). In elderly patients, meclofenoxate has been shown to improve performance on certain memory tests. [5]
For venous insufficiency, the dosage is 2 tablets of 500mg daily. For acute hemorrhoidal attack, the dosage is 6 tablets daily for 4 days, followed by 4 tablets daily over the next 3 days. [15] For chronic venous disease, the dosage is 2 tablets a day for at least 2 months. [16]
Levetiracetam, sold under the brand name Keppra among others, is a novel antiepileptic drug [7] used to treat epilepsy. [8] It is used for partial-onset, myoclonic, or tonic–clonic seizures, [7] and is taken either by mouth as an immediate or extended release formulation or by injection into a vein.
Diclofenac, sold under the brand name Voltaren among others, is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammatory diseases such as gout. [6] [9] It can be taken orally (swallowed by mouth), inserted rectally as a suppository, injected intramuscularly, injected intravenously, applied to the skin topically, or through eye drops.
The term "steroid dementia" was coined by Varney et al. (1984) in reference to the effects of long-term glucocorticoid use in 1,500 patients. [3] While the condition generally falls under the classification of Cushing's syndrome , the term "steroid dementia syndrome" is particularly useful because it recognizes both the cause of the syndrome ...
Its use was pioneered in the Czech Republic, where it was first noted that use greatly decreases mortality among elderly. [ 31 ] [ 32 ] In 2022, a large Phase 3 trial concluded that administration of inosine pranobex should start as early as possible with greatly improved outcomes in mild to moderate COVID-19 patients.
On 21 February 2014 the European Medicine Agency recommended that strontium ranelate remain available with restrictions relative to patients with existing heart disease. [4] In 2017, a large study of over 280,000 British and Spanish patients found no increased risk of venous thromboembolism in users of strontium ranelate compared to alendronate ...
Malnutrition and poor nutritional status is an area of concern, affecting 12% to 50% of hospitalized elderly patients and 23% to 50% of institutionalized elderly patients living in long-term care facilities such as assisted living communities and skilled nursing facilities. [20]